Affiliations: [a] King’s College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London, United Kingdom
| [b] Parkinson’s Foundation Centre of Excellence, King’s College Hospital, Denmark Hill, London, United Kingdom
| [c] Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, the Netherlands | [d] Department of Neurology, University Hospital Cologne, Cologne, Germany
Correspondence:
[*]
Correspondence to: Professor K Ray Chaudhuri, Department
of Basic and Clinical Neuroscience The Maurice Wohl Clinical
Neuroscience Institute King’s College London Cutcombe Road
London, SE5 9RT United Kingdom Tel: 0203299 8807, E-mail: ray.chaudhuri@kcl.ac.uk.
Abstract: Combined catechol-O-methyl-transferase-inhibition and Levodopa-Carbidopa intestinal gel (LCIG) infusion has the potential to reduce LCIG daily dose and the costs of this therapy. In this retrospective analysis, we report on Parkinson’s disease (PD) patients on LCIG with concomitant Opicapone. In 11 patients, the introduction of Opicapone led to LCIG daily dose being reduced by 24.8% (p = 0.05) without any significant worsening of dyskinesia. Three patients withdrew from Opicapone due to side effects or inefficacy. LCIG daily dose reduction could lead to cost savings of £142,820.63/year in the United Kingdom while maintaining clinical care.
